Combined treatment with anti‐PSMA CAR NK‐92 cell and anti‐PD‐L1 monoclonal antibody enhances the antitumour efficacy against castration‐resistant prostate cancer

• Published in: Clinical and translational medicine Vol. 12; no. 6; pp. e901 - n/a
• Main Authors: Wang, Fangming, Wu, Liyuan, Yin, Le, Shi, Hui, Gu, Yuchun, Xing, Nianzeng
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.06.2022; John Wiley and Sons Inc; Wiley
• Subjects: Antigens; Cancer therapies; CAR NK‐92 cell line; castration‐resistant prostate cancer; Clinical medicine; Flow cytometry; Gene expression; Kinases; Lymphocytes; Monoclonal antibodies; PD‐L1; Prostate cancer; Tumors; PD-L1; CAR NK-92 cell line; castration-resistant prostate cancer
• ISSN: 2001-1326; 2001-1326
• DOI: 10.1002/ctm2.901

Background The chimeric antigen receptor NK‐92 (CAR NK‐92) cell targeting the prostate‐specific membrane antigen (PSMA) has shown antitumour effects in castration‐resistant prostate cancer (CRPC). However, the expression changes of programmed death ligand 1 (PD‐L1) and its mechanisms on CAR NK‐92 and CRPC cells and the effect of the anti‐PD‐L1 monoclonal antibody (mAb) on PD‐L1 expressed on CAR NK‐92 cells remain unknown. Methods Human dendritic cells and CD8+ T cells were acquired from blood samples of healthy donors and cocultured with C4‐2 cells. Changes in PD‐L1 expression were detected by flow cytometry. Differential gene expressions were investigated by RNA sequence analysis, while the regulation of PD‐L1 molecular signaling was explored using western blotting. In vitro cytotoxicity was evaluated using the Cell Counting Kit‐8 assay and the bioluminescent intensity (BLI) of green fluorescent protein‐labelled C4‐2 cells. CRPC growth in vivo was monitored using callipers and BLI in male NOD/SCID mice subcutaneously injected with C4‐2 cells and treated intravenously with anti‐PD‐L1/PD‐1 mAb, CAR NK‐92 or cocultured CD8+ T cells. Results Significantly upregulated expression of PD‐L1k was observed in cocultured C4‐2 and CAR NK‐92 cells. In addition, upregulation of PD‐L1 expression was dependent on interferon‐γ in C4‐2 cells, while it was dependent on direct cell‐to‐cell interaction via the NK group 2 member D/ phosphatidylinositol 3‐kinase/AKT pathway in CAR NK‐92 cells. The anti‐PD‐L1 mAb directly acted on PD‐L1 expressed on CAR NK‐92 cells and augmented the cytotoxicity of CAR NK‐92 cells against C4‐2 and CRPC cells from one patient in vitro. Anti‐PD‐L1 mAb significantly enhanced the antitumour effect of CAR NK‐92 cells against CRPC cells in vivo when compared to treatment with CAR NK‐92 cells or combined with anti‐PD‐1 mAb in the absence or presence of cocultured CD8+ T cells. Conclusion Combined treatment with CAR NK‐92 and anti‐PD‐L1 mAb improved the antitumour efficacy against CRPC, which is of extraordinary translational value in the clinical treatment of CRPC.   CAR NK‐92 is activated through specific recognition of PSMA on prostate cancer cells. Expression of PD‐L1 on activated CAR NK‐92 is upregulated via CAR‐triggered PI3K/AKT/mTOR pathway. Expression of PD‐L1 on cancer cells is upregulated via IFN‐γ‐mediated JAK‐STAT pathway. Atezolizumab potentiates CAR NK‐92 cytotoxicity by directly acting on PD‐L1 on CAR NK‐92 and unleashes CD8+ T cell via blocking PD‐L1/PD‐1 axis.